Form D · Biotechnology
Virica Biotech Inc.
Ottawa, A6 · CIK 0001892496
Offering snapshot reported May 13, 2024 · SEC filing
- Reported sold
- $60K Indefinite offering
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 29, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 13, 2024 | Initial | $60,000 | No comparison | 2 | SEC filing |
| Jan 26, 2024 | Initial | $2,999,999 | No comparison | 2 | SEC filing |
| Jun 16, 2022 | Initial | $499,999 | No comparison | 1 | SEC filing |
| Nov 19, 2021 | Initial | $3,499,999 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-513078
Source: Form D, filed May 13, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Susan Dexter | Director |
| Jean Simon Dr. Diallo | Director, Executive |
| Ella Korets Smith | Executive |
| Daniella Kranjac | Director |
| Ken Newport | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7 Bayview Station Road
Ottawa, A6, K1Y 2C5
Ottawa, A6, K1Y 2C5